These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 3085738

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Impaired growth hormone response to sodium valproate in normal aging.
    Monteleone P, Iovino M, Orio F, Steardo L.
    Psychopharmacology (Berl); 1987; 91(1):10-3. PubMed ID: 3029790
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological activation of the GABAergic system does not affect GH and PRL release in acromegaly.
    Orio F, Iovino M, Monteleone P, Agrusta M, Steardo L, Lombardi G.
    Horm Metab Res; 1988 Nov; 20(11):701-4. PubMed ID: 2850985
    [Abstract] [Full Text] [Related]

  • 6. Different control of GH secretion by gamma-amino- and gamma-hydroxy-butyric acid in 4-year abstinent alcoholics.
    Vescovi PP, Coiro V.
    Drug Alcohol Depend; 2001 Feb 01; 61(3):217-21. PubMed ID: 11164685
    [Abstract] [Full Text] [Related]

  • 7. Alcoholism abolishes the gamma-aminobutyric acid (GABA)ergic control of GH secretion in humans.
    Vescovi PP, Volpi R, Coiro V.
    Alcohol; 1998 Nov 01; 16(4):325-8. PubMed ID: 9818985
    [Abstract] [Full Text] [Related]

  • 8. Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia.
    Monteleone P, Maj M, Ariano MG, Iovino M, Fiorenza L, Steardo L.
    Psychopharmacology (Berl); 1988 Nov 01; 96(2):223-6. PubMed ID: 3148149
    [Abstract] [Full Text] [Related]

  • 9. Reduction of baclofen-, but not sodium valproate-induced growth hormone release in type I diabetic men.
    Coiro V, Capretti L, Bianconi L, Castelli A, Cerri L, Roberti G, Marcato A, Volpi R, Chiodera P.
    Horm Metab Res; 1991 Dec 01; 23(12):600-4. PubMed ID: 1663914
    [Abstract] [Full Text] [Related]

  • 10. Different control mechanisms of growth hormone (GH) secretion between gamma-amino- and gamma-hydroxy-butyric acid: neuroendocrine evidence in Parkinson's disease.
    Volpi R, Chiodera P, Caffarra P, Scaglioni A, Saccani A, Coiro V.
    Psychoneuroendocrinology; 1997 Oct 01; 22(7):531-8. PubMed ID: 9373886
    [Abstract] [Full Text] [Related]

  • 11. Opioid modulation of the gamma-aminobutyric acid-controlled inhibition of exercise-stimulated growth hormone and prolactin secretion in normal men.
    Coiro V, Volpi R, Maffei ML, Caiazza A, Caffarri G, Capretti L, Colla R, Chiodera P.
    Eur J Endocrinol; 1994 Jul 01; 131(1):50-5. PubMed ID: 8038904
    [Abstract] [Full Text] [Related]

  • 12. Prolactin and growth hormone responses to growth hormone-releasing hormone in acute schizophrenia.
    Nerozzi D, Magnani A, Sforza V, Scaramucci E, Cerilli M, Moretti C, Antonozzi I, Frajese G.
    Neuropsychobiology; 1990 Jul 01; 23(1):15-7. PubMed ID: 2280826
    [Abstract] [Full Text] [Related]

  • 13. Evidence for a GABAergic control of the exercise-induced rise in GH in man.
    Steardo L, Iovino M, Monteleone P, Agrusta M, Orio F.
    Eur J Clin Pharmacol; 1985 Jul 01; 28(5):607-9. PubMed ID: 3930260
    [Abstract] [Full Text] [Related]

  • 14. Effect of gamma-aminobutyric acid on growth hormone and prolactin secretion in man: influence of pimozide and domperidone.
    Cavagnini F, Benetti G, Invitti C, Ramella G, Pinto M, Lazza M, Dubini A, Marelli A, Müller EE.
    J Clin Endocrinol Metab; 1980 Oct 01; 51(4):789-92. PubMed ID: 7419665
    [Abstract] [Full Text] [Related]

  • 15. The effect of methysergide, pimozide, and sodium valproate on the diazepam-stimulated growth hormone secretion in man.
    Koulu M, Lammintausta R, Kangas L, Dahlström S.
    J Clin Endocrinol Metab; 1979 Jan 01; 48(1):119-22. PubMed ID: 370137
    [Abstract] [Full Text] [Related]

  • 16. Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist.
    Tamminga CA, Neophytides A, Chase TN, Frohman LA.
    J Clin Endocrinol Metab; 1978 Dec 01; 47(6):1348-51. PubMed ID: 162520
    [Abstract] [Full Text] [Related]

  • 17. Effects of a GABA-mimetic drug (sodium valproate) on visually evoked potentials in chronic schizophrenics.
    Kausen J, Zimmermann P, Fünfgeld EW, Klenke D, Henkel H.
    Neuropsychobiology; 1984 Dec 01; 11(1):59-64. PubMed ID: 6146111
    [Abstract] [Full Text] [Related]

  • 18. Failure of the gamma-aminobutyric acid (GABA) derivative, baclofen, to stimulate growth hormone secretion in Parkinson's disease.
    Volpi R, Scaglioni A, Marcato A, Caffarra P, Rossi G, Caffarri G, Delsignore R, Chiodera P, Coiro V.
    J Neural Transm Park Dis Dement Sect; 1991 Dec 01; 3(4):259-64. PubMed ID: 1772578
    [Abstract] [Full Text] [Related]

  • 19. Influence of sodium valproate on medium-late luteal phase pulsatile LH secretion in normal women.
    Lado Abeal J, Rey Losada C, Cabezas Agricola JM, Cabezas-Cerrato J.
    Clin Endocrinol (Oxf); 1994 Jan 01; 40(1):127-31. PubMed ID: 8306471
    [Abstract] [Full Text] [Related]

  • 20. Neuroendocrine effects of chronic administration of sodium valproate in epileptic patients.
    Invitti C, Danesi L, Dubini A, Cavagnini F.
    Acta Endocrinol (Copenh); 1988 Jul 01; 118(3):381-8. PubMed ID: 2839946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.